Vertex Pharmaceuticals Incorporated (VRTX)
Pre-market:
| Previous close | 297.87 |
| Open | 301.95 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 300.67 - 305.47 |
| 52-week range | 233.01 - 325.19 |
| Volume | |
| Avg. volume | 1,253,668 |
| Market cap | 78.348B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 23.09 |
| EPS (TTM) | 13.20 |
| Earnings date | 03 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 334.08 |
- Zacks
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
This Cathie Wood Stock Could Nearly Double, According to Wall Street
One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP). This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood. Wood isn't the only one on Wall Street who likes CRISPR.
- Motley Fool
This Is My Highest-Conviction Stock to Own in 2023 and Beyond
While one could say the same about many biotech companies, Vertex has an advantage very few of its peers do: For CF patients, it's the only game in town. Vertex markets the only medicines that target the underlying causes of CF. In 2022, the company's revenue of $8.93 billion jumped by 18% year over year.
